Jianmin Ding1, Yan Zhou1, Yandong Wang1, Xiang Jing1, Fengmei Wang2, Yijun Wang3. 1. Department of Ultrasound, Tianjin Third Central Hospital, Tianjin Key Laboratory of Artificial Cell, Tianjin, China. 2. Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin, China. 3. Department of Hepatobiliary Surgery, Tianjin Third Central Hospital, Tianjin, China.
Abstract
BACKGROUND & AIMS: To explore the long-term outcomes and safety of ultrasound-guided percutaneous microwave ablation (MWA) of exophytic tumours in hepatocellular carcinoma (HCC) patients. METHODS: One hundred and thirty-two patients with subcapsular HCC were enrolled in this retrospective study. These patients were divided into the exophytic group (n=71) and non-exophytic group (n=61) according to the location of the tumour(s). A special technology of puncture and ablation was performed to treat the exophytic tumours. The local tumour progression (LTP), progression free survival (PFS) and overall survival (OS) were analysed using Kaplan-Meier and Log-rank tests. RESULTS: Sixty-nine of 71 exophytic tumours and 60 of 61 subcapsular tumours were completely ablated. The complete ablation rates were 97.2% and 98.4% respectively. The follow-up periods ranged from 6 to 62 months with a median of 31 months in the exophytic group, and ranged from 5 to 61 months, with a median of 27 months in the non-exophytic group. The 1-, 3- and 5-year cumulative LTP rates were 2.4%, 12.3%, 18.4% and 5.1%, 12.0%, 17.8% in the exophytic and non-exophytic groups respectively (P=.733). The 1-, 3- and 5-year OS rates were 100%, 75.7%, 52.9% and 95.0%, 73.8%, 61.5% in the exophytic group and non-exophytic group respectively (P=.980). There was no procedure-related mortality or major complication. CONCLUSION: Ultrasound-guided percutaneous MWA is safe and effective for exophytic tumours in HCC patients. Treated by MWA, the HCC patients with exophytic tumours can get the similar local response and long-term outcome to those with non-exophytic subcapsular tumours.
BACKGROUND & AIMS: To explore the long-term outcomes and safety of ultrasound-guided percutaneous microwave ablation (MWA) of exophytic tumours in hepatocellular carcinoma (HCC) patients. METHODS: One hundred and thirty-two patients with subcapsular HCC were enrolled in this retrospective study. These patients were divided into the exophytic group (n=71) and non-exophytic group (n=61) according to the location of the tumour(s). A special technology of puncture and ablation was performed to treat the exophytic tumours. The local tumour progression (LTP), progression free survival (PFS) and overall survival (OS) were analysed using Kaplan-Meier and Log-rank tests. RESULTS: Sixty-nine of 71 exophytic tumours and 60 of 61 subcapsular tumours were completely ablated. The complete ablation rates were 97.2% and 98.4% respectively. The follow-up periods ranged from 6 to 62 months with a median of 31 months in the exophytic group, and ranged from 5 to 61 months, with a median of 27 months in the non-exophytic group. The 1-, 3- and 5-year cumulative LTP rates were 2.4%, 12.3%, 18.4% and 5.1%, 12.0%, 17.8% in the exophytic and non-exophytic groups respectively (P=.733). The 1-, 3- and 5-year OS rates were 100%, 75.7%, 52.9% and 95.0%, 73.8%, 61.5% in the exophytic group and non-exophytic group respectively (P=.980). There was no procedure-related mortality or major complication. CONCLUSION: Ultrasound-guided percutaneous MWA is safe and effective for exophytic tumours in HCCpatients. Treated by MWA, the HCCpatients with exophytic tumours can get the similar local response and long-term outcome to those with non-exophytic subcapsular tumours.